The Motley Fool
13 Jun 2026, 04:15 UTC · 20w ago
Impact · against what's priced in
Boston Scientific faces significant downward pressure as management repeatedly lowers organic revenue guidance and forecasts flat growth for Q2 and Q3. The analyst price targets provide little immediate support as the stock price reflects a severe erosion of growth momentum.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Boston Scientific CEO Michael Mahoney indicated the company will likely report flat dollar growth for the second and third quarters.
More negative than 95% of claims this week
Boston Scientific has repeatedly lowered organic revenue guidance throughout the year, most recently reducing the 2026 outlook to between 6.5% and 8%.
Continue reading
5 related stories
The company has repeatedly cut 2026 organic revenue guidance to 6.5%-8% and now expects flat dollar growth for the second and third quarters due to declining Watchman procedure usage.
Read from the article alone
Scored by the NIS engine · methodology.
More negative than 91% of claims this week
The decline in growth is partially attributed to the decreasing usage of Watchman stand-alone heart implant procedures.
More negative than 79% of claims this week
Despite the stock's decline, 27 out of 31 analysts maintain a buy rating with a consensus price target of $78, suggesting a potential 65% upside.
More positive than 48% of claims this week
Which stocks this story touches
More negative than 92% of ticker scores this week
The company has seen significant share price declines and has repeatedly lowered growth expectations and revenue guidance.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a peer for valuation comparison and as a recommended holding by the author's firm.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a peer for valuation comparison and as a recommended holding by the author's firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
22m ago
More positive than 33% of relationship scores this week
[mutual] Boston Scientific is compared to Abbott Laboratories as being in the same medical device stock category.
More positive than 33% of relationship scores this week
[mutual] Boston Scientific is compared to Medtronic as being in the same medical device stock category.
−6.1%
Price agrees with the score
$44.05 vs $46.91 close before publication (Jun 12) · not market-adjusted
BSX chart →
